Results

Total Results: 3,706 records

Showing results for "diabetes treatment".
Users also searched for: diabetes guidelines

2281. A Comparison of All-Cause 7-Day and 30-Day Readmissions, 2014 #230
      hcup-us.ahrq.gov/reports/statbriefs/sb230-7-Day-Versus-30-Day-Readmissions.jsp
      October 01, 2017 - 7 7.1 11 19.5 Acute and unspecified renal failure 436,833 8 7.0 8 20.1 Diabetes … Pancreatic disorders (not diabetes) (7-day readmission rate=6.2): 36.1%. … Diabetes mellitus with complications (7-day readmission rate=6.9): 33.7%. … However, if a patient received long-term care, rehabilitation, or treatment for a psychiatric or chemical … quality of health services, medical practice patterns, access to healthcare programs, and outcomes of treatments

2282. Ym2Epescwzwnpaamr78Shp (pdf file)
      www.uspreventiveservicestaskforce.org/home/getfilebytoken/Ym2epesCwZWNPaaMr78Shp
      August 01, 2014 - Factors associated with a reduced risk for AAA include African American race, Hispanic ethnicity, and diabetes … Short-term treatment with antibiotics or -blockers does not seem to reduce AAA growth. … Factors associated with a reduced risk include African American race, Hispanic ethnicity, and diabetes … Appropriately powered studies that can assess health outcomes should evaluate whether such treatments … Treatment Studies Standard Intervention for Large (�5.5 cm) AAAs.

2283. Evidence-based Practice Center Systematic Review Protocol (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/chronic-kidney-disease-anemia-2011_research-protocol.pdf
      January 01, 2011 - iron therapy is preferred over oral therapy because it decreases ESA dosages and significantly increases … What targets of iron therapy should be achieved? … is usually determined by their indirect effects on outcomes, that is, through their influence on therapeutic … regimen (i.e., repletion or continuous treatment)  Interactions between treatments (i.e., patients … Bethesda, MD, National Institute of Diabetes and Digestive and Kidney Diseases; 2010.

2284. Presentation: Building Your SSI Prevention Bundle
      www.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/hais/tools/surgery/modules/onboarding/onboarding_build_ssibundle.pptx
      December 01, 2017 - Host risk factors include malnutrition, chemotherapy treatment, immunosuppressant medications, or steroids—all … The goal is to maintain therapeutic levels throughout the entire case. … Efficacy Standardize weight-based dosing of cephalosporins Standardize antibiotics redosing Maintain therapeutic … You can look at patients with diabetes — does your hospital have a policy? … Do you check glucose levels of patients with diabetes in the prep area?

2285. HCUP Statistical Brief #123: Components of Growth in Inpatient Hospital Costs, 1997-2009 (pdf file)
      hcup-us.ahrq.gov/reports/statbriefs/sb123.pdf
      November 01, 2011 - 0.7 $1.9 $3.2 4.5% 13.6 9.3 $3.8 $4.2 0.9% Previous C‐section 1.1 2.0 $0.9 $2.4 8.2% NA NA NA NA NA Diabetes … Complications of surgical procedures or medical care Congestive heart failure Nonspecific chest pain Diabetes … Chronic obstructive pulmonary disease and bronchiectasis Congestive heart failure, nonhypertensive Diabetes … Classifications Software (CCS) The principal procedure is the procedure that was performed for definitive treatment

2286. Archived: Folic Acid to Prevent Neural Tube Defects: Preventive Medication | United States Preventive Services Taskforce
      www.uspreventiveservicestaskforce.org/uspstf/recommendation/folic-acid-to-prevent-neural-tube-defects-preventive-medication-2009
      May 15, 2009 - defect The use of certain antiseizure medications Mutations in folate-related enzymes Maternal diabetes … Other reported risk factors include mutations in folate-related enzymes, maternal diabetes, and obesity … rates of neural tube defects than black and Asian persons. 5 Maternal medical conditions, such as diabetes … association of folic acid supplementation with twinning is the result of confounding by infertility treatment

2287. Hospitalizations in which Patients Leave the Hospital against Medical Advice (AMA), 2007 (pdf file)
      hcup-us.ahrq.gov/reports/statbriefs/sb78.pdf
      August 01, 2009 - ■ Nonspecific chest pain and diabetes with complications were 3.6 and 2.7 times more common in … stresses, family emergencies, self-assessment of their health status, or dissatisfaction with their treatment … hospital stay may be avoided with effective and timely ambulatory care: nonspecific chest pain and diabetes … Substance-related disorders 21,000 (5.7) 207,900 (0.5) 10.8 4 Mood disorders 13,900 (3.8) 760,400 (1.9) 1.9 5 Diabetes

2288. 2021 National Healthcare Quality and Disparities Report Data Sources (pdf file)
      www.ahrq.gov/sites/default/files/wysiwyg/research/findings/nhqrdr/2021qdr-datasources.pdf
      December 31, 2021 - quality of health services, medical practice patterns, access to healthcare programs, and outcomes of treatments … The large sample size in the enables analyses of rare conditions, uncommon treatments, and special patient … To evaluate the outcomes of TB therapy, RVCT Follow up Report-2 was added. … and where, and • Reason therapy was extended for more than 12 months. … their diabetes care, such as services rendered

2289. Medical-Evidence-Communication Research-Protocol (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/medical-evidence-communication_research-protocol.pdf
      July 31, 2012 - creates multiple challenges, including difficulties: (1) determining whether preventive services and treatments … benefits, and treatment harms. … National Institutes of Health (e.g., National Heart, Lung and Blood Institute; National Institute of Diabetes … “A lack of activity increases risk for diabetes.” … We will also consider studies that compare ways to explain net benefit (of prevention or therapeutic

2290. Maskedstats Nrd 2018 Severity (pdf file)
      hcup-us.ahrq.gov/db/nation/nrd/stats/MaskedStats_NRD_2018_Severity.PDF
      January 01, 2018 - 10,126 0.06% 405: Other procedures for endocrine, nutritional & metabolic disorders 4,383 0.02% 420: Diabetes … dependence, left against medical advice 29,984 0.17% 772: Alcohol & drug dependence w rehab or rehab/detox therapy … Other drug abuse & dependence 19,928 0.11% 792: Extensive OR procedures for other complications of treatment … 11,979 0.07% 793: Moderately extensive OR procedures for other complications of treatment 18,804 0.11% … 794: Non-extensive OR procedures for other complications of treatment 3,399 0.02% 810: Hemorrhage

2291. Kid 2019 Maskedstats Severity V2 (pdf file)
      hcup-us.ahrq.gov/db/nation/kid/tools/stats/KID_2019_MaskedStats_Severity_V2.PDF
      January 01, 2019 - Percent of Total 405: Other procedures for endocrine, nutritional & metabolic disorders 327 0.01% 420: Diabetes … dependence, left against medical advice 378 0.01% 772: Alcohol & drug dependence w rehab or rehab/detox therapy … Other drug abuse & dependence 3,251 0.11% 792: Extensive OR procedures for other complications of treatment … 1,752 0.06% 794: Non-extensive OR procedures for other complications of treatment 228 0.01% 810: Hemorrhage … reactions 2,288 0.07% 812: Poisoning of medicinal agents 7,978 0.26% 813: Other complications of treatment

2292. Maskedstats Nis 2019 Severity V2 (pdf file)
      hcup-us.ahrq.gov/db/nation/nis/tools/stats/MaskedStats_NIS_2019_Severity_V2.PDF
      January 01, 2019 - of Total 405: Other procedures for endocrine, nutritional & metabolic disorders 1,677 0.02% 420: Diabetes … dependence, left against medical advice 10,231 0.14% 772: Alcohol & drug dependence w rehab or rehab/detox therapy … APRDRG APRDRG Frequency Percent of Total 792: Extensive OR procedures for other complications of treatment … 4,488 0.06% 793: Moderately extensive OR procedures for other complications of treatment 6,936 0.10% … 794: Non-extensive OR procedures for other complications of treatment 1,257 0.02% 810: Hemorrhage

2293. Maskedstats Nis 2018 Severity (pdf file)
      hcup-us.ahrq.gov/db/nation/nis/tools/stats/MaskedStats_NIS_2018_Severity.PDF
      January 01, 2018 - 3,460 0.05% 405: Other procedures for endocrine, nutritional & metabolic disorders 1,664 0.02% 420: Diabetes … dependence, left against medical advice 10,036 0.14% 772: Alcohol & drug dependence w rehab or rehab/detox therapy … Other drug abuse & dependence 7,062 0.10% 792: Extensive OR procedures for other complications of treatment … 4,505 0.06% 793: Moderately extensive OR procedures for other complications of treatment 6,959 0.10% … 794: Non-extensive OR procedures for other complications of treatment 1,270 0.02% 810: Hemorrhage

2294. Recommendation: Folic Acid Supplementation to Prevent Neural Tube Defects: Preventive Medication | United States Preventive Services Taskforce
      www.uspreventiveservicestaskforce.org/uspstf/recommendation/folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication
      August 01, 2023 - certain antiseizure medicines, and genetic mutations in folate-related enzymes. 15-19 Pregestational diabetes … A subgroup of participants (123 cases and 1306 controls) with pregestational diabetes and prepregnancy … Spectrum of congenital anomalies in pregnancies with pregestational diabetes. … Rationale Assessment Benefits of intervention and treatment … Harms of early detection and intervention and treatment The USPSTF found adequate evidence that folic

2295. Folic Acid Supplementation to Prevent Neural Tube Defects: US Preventive Services Task Force Reaffirmation Recommendation Statement (pdf file)
      www.uspreventiveservicestaskforce.org/home/getfilebytoken/guxuobDFwkzk5YJWU5ZQkw
      August 01, 2023 - certain antiseizure medicines, and genetic mutations in folate-related enzymes.15-19 Pregestational diabetes … A subgroup of participants (123 cases and 1306 controls) with pregestational diabetes and prepregnancy … Summary of USPSTF Rationale Rationale Assessment Benefits of intervention and treatment The USPSTF … Harms of early detection and intervention and treatment The USPSTF found adequate evidence that folic … Spectrum of congenital anomalies in pregnancies with pregestational diabetes.

2296. AHRQ Multiple Chronic Conditions Research Summit: Speaker Biosketches | Agency for Healthcare Research and Quality
      www.ahrq.gov/patient-safety/settings/long-term-care/resource/multichronic/summit-bios.html
      November 01, 2021 - As a certified Master Gardener, she volunteers in therapeutic horticulture programs. … Goldberg Young Investigator Award from the American Society of Clinical Pharmacology and Therapeutics … She has extensive training in evidence-based treatments, particularly for children and adolescents. … variations and the relationship between patients’ social, functional, and medical characteristics and treatment … i.e., the use of strategies to help providers scale up and spread effective practices in real-world treatment

2297. Cer-238-Cervical-Ripening-Appendix-E-2 (xls file)
      effectivehealthcare.ahrq.gov/sites/default/files/cer-238-cervical-ripening-appendix-e-2.xlsx
      January 01, 2017 - through the trial following an adverse fetal outcome, leading to exclusion of women with diet-controlled diabetes … through the trial following an adverse fetal outcome, leading to exclusion of women with diet-controlled diabetes … 0.34 to 1.28) Frequency of newborn complications requiring >3 day hospitalization: "unaffected by" OP therapy … admission: 31.58% (18/57) vs. 31.75% (20/63) RR 0.99 (95% CI 0.59 to 1.68) NR NR Reminder: all patients had diabetes … lactate (26 silicone, 20 latex), congenital condition (15 silicone, six latex), maternal gestational diabetes

2298. Management of Uterine Fibroids - Evidence Summary (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/evidence-summary-cer-195-uterine-fibroids-final.pdf
      December 01, 2017 - Four studies evaluated therapies in postmenopausal women. … Among medical therapies, GnRH agonists, mifepristone, and ulipristal reduced fibroid size and improved … trajectories in which all initial treatments can be followed by all possible combinations of next treatments … uterine fibroids, growth patterns, and influences on growth (e.g., concurrent medical conditions like diabetes … No data is available to indicate whether use of therapeutics short of surgery might forestall or prevent

2299. Screening for Latent Tuberculosis Infection in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force (pdf file)
      www.uspreventiveservicestaskforce.org/home/getfilebytoken/oPmYxryXGu2occANaReagc
      August 01, 2022 - isoniazid and 1.1% for rifampin.131 Meta-analysis found no statistically significant difference between treatments … It is unclear whether changes in the prevalence of tuberculosis (which has decreased), treatments for … noninferiority, improved adherence, and lower risk of hepa- totoxicity for current, CDC-preferred LTBI treatments … The sensitivity of interferon-gamma release assays is not compromised in tuberculosis patients with diabetes … Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis

2300. Integrating patient-reported outcomes and electronic health record data to improve clinical decision support for depression treatment - Final Report (pdf file)
      digital.ahrq.gov/sites/default/files/docs/citation/r21hs021769-anderson-final-report-2016.pdf
      January 01, 2016 - medication-related side effects, depression severity, medication adherence, and receipt of cognitive behavioral therapy … medication-related side effects, depression severity, medication adherence, and receipt of cognitive behavioral therapy … , even though effective treatment options exist. … results in decreased risk of physical disability, medical conditions such as coronary heart disease and diabetes … The economic burden of depression and the cost- effectiveness of treatment.